Celgenes Tecentriq Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in Phase 3 TNBC Trial

SUMMIT N.J.&8211;BUSINESS WIRE&8211;Celgene Corporation NASDAQCELG today announced that the Phase III IMpassion130 study which was sponsored by Roche met its coprimary endpoint of progressionf…
Read the full story: Bioportfolio Latest News